Latest News
Heron Therapeutics, Inc.
- Form 4 Heron Therapeutics Inc: Ira Duarte (EVP, Chief Financial Officer) For: 19 October
- Heron Therapeutics CEO Craig Collard Converts 13,797 RSUs, Withholds 3,360 Shares for Taxes on Oct 19, 2026
- Quarterly stock vesting gives Heron Therapeutics (HRTX) development chief 3,874 shares.
- Stock awards convert into 13,797 shares for Heron Therapeutics (HRTX) CEO Craig A. Collard.
- MarketBeat estimates November 3 results for Heron Therapeutics stock
- Heron Therapeutics: Acute Care Growth Offset by Oncology Weakness and Financial Uncertainty
- Heron Therapeutics, Inc. (HRTX) - What Are Investment Firms Thinking About This Stock?
- Heron Therapeutics stock sits 77.22 percent below its 52-week high
- Daily Options Flow Leaderboard | EWZS Extends Its Call-Volume Lead, and Heron Therapeutics Sees Heavy Put Selling
- Form 8K Heron Therapeutics Inc For: 29 September By Investing.com
- Heron Therapeutics (HRTX) Edges Higher: Penny Stock Holds Ground Above $0.30 - Breadth Thrust
- Heron Therapeutics signs multi-product license agreement with Long Grove
Headlines from the last 30 days, linking to the original publishers. See all market news →